A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent

Vivek Daniel Paul1, Sanjeev Saravanan Rajagopalan, Sudarson Sundarrajan

  • 1Gangagen Biotechnologies Pvt Ltd, Raghavendra Layout, Tumkur Road, Yeshwantpur, Bangalore 560022, India.

BMC Microbiology
|October 12, 2011
PubMed
Abstract

Insights

Researchers identified a phage K gene encoding a muralytic enzyme (TAME) with potent antibacterial activity against Staphylococcus aureus. A modified enzyme, P128, effectively targets and kills antibiotic-resistant strains, including in vivo models.

Area of Science:

  • Microbiology
  • Biochemistry
  • Molecular Biology

Background:

  • Staphylococcus aureus is a significant cause of hospital and community infections.
  • Antibiotic resistance in S. aureus limits treatment options.
  • Bacteriophage-derived muralytic enzymes show promise against resistant gram-positive bacteria.

Purpose of the Study:

  • Identify and characterize novel antibacterial agents from bacteriophages.
  • Develop a potent therapeutic agent against antibiotic-resistant S. aureus.
  • Evaluate the efficacy of a novel chimeric protein in vitro and in vivo.

Main Methods:

  • Identified a gene (orf56) encoding a phage tail-associated muralytic enzyme (TAME) from bacteriophage K.
  • Characterized the muralytic activity of the TAME's CHAP domain.
  • Constructed a chimeric protein (P128) by combining a truncated TAME (Lys16) with an SH3b cell-wall binding domain.

Main Results:

  • The TAME's C-terminal CHAP domain exhibited muralytic activity and was lethal to S. aureus.
  • The chimeric protein P128 demonstrated potent antistaphylococcal activity against diverse clinical isolates, including MRSA.
  • P128 effectively reduced S. aureus USA300 nasal colonization in a rat model.

Conclusions:

  • A novel phage K-derived muralytic enzyme (TAME) with bactericidal activity against S. aureus was identified.
  • The chimeric protein P128, combining TAME with a cell-wall binding domain, shows broad-spectrum efficacy against S. aureus.
  • P128 is a promising candidate for treating infections caused by antibiotic-resistant S. aureus, demonstrating in vivo efficacy.

Related Concept Videos

DNA Bacteriophages01:26

DNA Bacteriophages

Bacteriophages, or phages, are viruses that specifically infect bacteria, utilizing their genetic material to hijack host cellular machinery for replication. DNA bacteriophages employ single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA) genomes. These phages exhibit diverse replication strategies and host interactions, influencing their ecological roles and applications in biotechnology and medicine.ssDNA BacteriophagesssDNA phages, with their small genomes, utilize unique strategies to...
Viral Replication: Lytic Cycle01:20

Viral Replication: Lytic Cycle

Bacteriophages, or phages, are viruses that specifically infect bacteria. Among them, T-even bacteriophages, such as T4, exhibit a well-characterized lytic replication cycle in Escherichia coli (E. coli). This process ensures the rapid proliferation of the virus while ultimately leading to the destruction of the bacterial host.Attachment and DNA InjectionThe infection process begins with the recognition and binding of the T4 phage to the E. coli cell surface. Tail fibers of the phage...
Bacterial Protein Maturation01:26

Bacterial Protein Maturation

Bacterial protein maturation is a tightly regulated process that ensures newly synthesized polypeptides achieve correct functional conformations. This maturation involves a series of modifications, folding events, and quality control steps, often assisted by specialized chaperone proteins.N-Terminal ModificationsThe maturation of bacterial polypeptides begins cotranslationally as the polypeptide exits the ribosome. The first amino acid, N-formylmethionine (fMet), is typically modified at the...